Heritage Bio Labs
Research Library
Explore 411 articles about peptides, research compounds and related topics, with links to the original studies.
Find articles
All articles
Showing 301–312 of 411 articles
- Interpret the evidence
What a Rat Navigation Study Can Tell Us About Pinealon and Learning
Pinealon, also called EDR, is a three-amino-acid peptide. An older study examined how young and old rats performed on a navigation task after exposure to Pinealon or a different preparation.
Pinealon1 source (2013)
- Check methods and identity
Why Biological Age Measures Do Not Establish That Pinealon Extends Life
Pinealon is a three-amino-acid peptide also known as EDR. An older human report examined Pinealon and another peptide preparation, Vesugen, in people with several chronic conditions. It is useful for understanding what the researchers meant by biological age.
Pinealon1 source (2015)
- Check methods and identity
What the Current US Bremelanotide Label Covers
PT-141 is a name used for bremelanotide, a cyclic peptide that activates melanocortin receptors. A defined prescription product, Vyleesi, is FDA approved for a specific condition. The October 2026 US prescribing information explains which people and circumstances were included in that indication.
PT-1411 source (2026)
- Check methods and identity
How Two Phase 3 Trials Measured Desire and Distress Separately
Bremelanotide, also called PT-141, is a melanocortin receptor agonist. Two older phase 3 studies directly tested the prescription candidate in premenopausal women with hypoactive sexual desire disorder. The 2026 label still summarizes these pivotal comparisons.
PT-1412 sources (2019, 2026)
- Check methods and identity
What the 2026 Bremelanotide Label Reports About Safety
PT-141 is also known as bremelanotide. The October 2026 US label for the approved product, Vyleesi, records safety findings from its clinical evaluation. Those findings apply to that specific drug product and the settings in which it was studied.
PT-1411 source (2026)
- Understand the science
What a Receptor Structure Can Explain About PT-141
Bremelanotide, also called PT-141, is a cyclic peptide in the melanocortin research family. The current US label describes it as a melanocortin receptor agonist.
PT-1412 sources (2021, 2026)
- Explore study findings
What Participants Reported After the Bremelanotide Trials
Bremelanotide, also called PT-141, was evaluated in the RECONNECT trials for hypoactive sexual desire disorder. An older exit-study report examined what some trial participants said about their experience.
PT-1412 sources (2021, 2026)
- Interpret the evidence
Why the Bremelanotide Extension Study Cannot Replace a Placebo Comparison
PT-141, or bremelanotide, had a 52-week extension after the controlled phase of the RECONNECT studies. The older extension is the direct source for this comparison of study designs. Its results should be read alongside the current US labeling.
PT-1412 sources (2019, 2026)
- Understand the science
How two retatrutide trials counted breathing interruptions during sleep
Retatrutide is an investigational peptide that activates the GIP, GLP-1 and glucagon receptors. “RETA GLP-3” is a catalog label. Its number does not name a receptor target. A 2026 report examined retatrutide in adults with moderate to severe obstructive sleep apnea.
RETA GLP-33 sources (2025, 2026)
- Explore study findings
What TRIUMPH-1 established about average weight change
Retatrutide activates the GIP, GLP-1 and glucagon receptors, the three targets behind its description as a triple agonist. The “GLP-3” catalog wording refers to the entry, while the scientific names identify the receptors studied.
RETA GLP-32 sources (2025, 2026)
- Explore study findings
Why TRIUMPH-2 enrolled adults with type 2 diabetes
Retatrutide is an investigational peptide that activates GIP, GLP-1 and glucagon receptors. “GLP-3” is catalog wording for this triple agonist. The 2026 TRIUMPH-2 report asked what happened to body weight in participants who had both type 2 diabetes and excess body weight.
RETA GLP-32 sources (2026)
- Check methods and identity
What a three-sample retatrutide analysis showed about labeling
Retatrutide is an investigational peptide that activates the GIP, GLP-1 and glucagon receptors. The “GLP-3” wording is a catalog label. A 2026 Australian paper examined a different question from the clinical trials.
RETA GLP-32 sources (2026)
Browse by product
- A4 Amyloid Beta6 articles
- ACE-0316 articles
- ACE-0836 articles
- Adipotide6 articles
- AICAR6 articles
- AOD-96046 articles
- ARA-2906 articles
- BPC-1576 articles
- BPC-157 / TB-5006 articles
- Cagrilintide7 articles
- CJC-1295 (No DAC) / GHRP-26 articles
- CJC-1295 (No DAC) / GHRP-66 articles
- CJC-1295 (No DAC) / Ipamorelin6 articles
- CJC-1295 No DAC6 articles
- CJC-1295 With DAC6 articles
- DSIP6 articles
- Epitalon6 articles
- Follistatin 3156 articles
- Follistatin 3446 articles
- Fragment 176-1916 articles
- GHK-Cu6 articles
- GHRP-26 articles
- GHRP-66 articles
- GLOW 2 Blend6 articles
- GLOW Blend6 articles
- GLP-1 SEMA6 articles
- GLP-2 TIRZ6 articles
- Glutathione6 articles
- HCG6 articles
- Hexarelin6 articles
- Human Relaxin-26 articles
- IGF-1 DES 1,36 articles
- IGF-1 Human6 articles
- IGF-2 LR36 articles
- IGF-DES 1,36 articles
- IGF-LR36 articles
- Ipamorelin6 articles
- Kisspeptin-106 articles
- KLOW Blend6 articles
- KPV6 articles
- Lipopeptide6 articles
- Liraglutide6 articles
- Melanotan II5 articles
- MGF6 articles
- MOTS-C6 articles
- MSC Exosomes6 articles
- Myostatin6 articles
- Myostatin HMP (GDF8)6 articles
- Oxytocin7 articles
- PEG-MGF6 articles
- Pinealon6 articles
- PT-1416 articles
- RETA / IGF-1 LR36 articles
- RETA GLP-36 articles
- Selank6 articles
- SEMA / IGF-1 LR36 articles
- Semax6 articles
- Sermorelin6 articles
- SLU-PP-3326 articles
- SNAP-86 articles
- Survodutide7 articles
- TB-5006 articles
- Tesamorelin6 articles
- Thymosin Alpha-16 articles
- TIRZ / IGF-1 LR36 articles
- TIRZ GLP-26 articles
- Trevogrumab6 articles
- Triptorelin GnRH6 articles
